Shreya Life Science ends 2016 with Double Awards, founder Chairman Sujit Singh voted as “Visionary Entrepreneur of the Year” while dynamic Sheel Kumar Singh was awarded as “Inspiring Business Leader of the Year 2016” at Pharma Leaders Power Brand Awards
The dynamic duo of Shreya Life Sciences both Sujit Singh & Sheel Singh shined at asia’s most prestigious annual healthcare awards 2016 for outstanding & dynamic leadership in steering Shreya’s business both domestic, international & contract manufacturing business.
Mumbai based Shreya Life sciences, one of the fastest growing pharma company with a turnover of more than 500 crore having strong presence in domestic market & formidable overseas presence specially in CIS countries received top recognition when the founder chairman of the company Sujit Kumar Singh & Director of the shreya group Sheel Kumar Dhananjay Singh were awarded at the glittering annual award ceremony of Pharma Leaders Power Brand awards considered to be most credible & prestigious. The Trophy & Citations was received from the hands of Dr. Mukesh Batra, Chairman, Dr Batras & satya brahma, chairman & editor-in-chief, pharma leaders group where more than 400 industry leaders were present on friday, 23rd december 2016 at hotel sahara star.The set of 40 awards ware conferred to the top leaders & companies. Nation’s top healthcare leaders, pharma experts, policy makers, renowned doctors, social activists, bureaucrats & professionals of the Indian pharmaceutical & healthcare leaders assembled to witness the 9th annual pharmaceutical leadership summit & pharma Leaders business leadership awards 2016 organised by Network 7 Media Group’s Pharmaleaders, asia’s most analytical news media in healthcare communications
The institution, Pharma Leaders honors the principles and prominent leadership of the healthcare global leaders, decision makers, and various organizations that are path breakers of leadership excellence. It focuses on the remarkable achievements & noteworthy influence of the pharma leaders, and also throws light on the pivotal role played by the iconic healthcare leaders in leading the healthcare transformation to the threshold of the new world. It aims to make a quantum leap and a comprehensive approach in the performance of all those have contributed immensely to make their vision a great success, and who were able to take the maximum advantage of the opportunities available to them regionally and internationally and making the best out of those opportunities.
About Shreya Life Sciences
Shreya Life Sciences, the Indian arm of Shreya Group started its operations in India in the year 2001 by acquiring the Pharma Division of Rallis India Ltd., a TATA Group company. In 2003, Shreya acquired the domestic pharma business of Plethico Pharmaceuticals Ltd., with a view to achieve a full-fledged national presence. Shreya Life Sciences Pvt., Ltd. engages in the distribution of medicaments and medical products. The company sells its products ranging from anti-spasmodics and insulin to drugs for rheumatic arthritis. The company was incorporated in 1991 and is based in Mumbai, India. Shreya Life Sciences Pvt., Ltd. operates as a subsidiary of Shreya Corporation PJSC. Shreya Corporation currently boasts of distributing widest range of medicaments and medical products, including more than 4,500 medicines of all pharmacological groups. The company has direct contacts with more than 300 pharmaceutical enterprises among which there are the largest national and foreign manufacturers. Shreya is an agent for some of top MNCs like GSK, Merck, Aventis, and Sanofi Synthelabo. It has also partnered for Indian companies like Ranbaxy ( Now Sun Pharma ), Dr. Reddy’s Labs and JB Chemicals in Russia. Mumbai headquartered Shreya Life Sciences today generates revenue of more than Rs 500 crore turnover, of which more than one-third proportion has been from the company’s exports to the parent company in Russia
- Shreya has strategic alliance with Bio Technology General Corporation, USA,
- through SciGen, Singapore and Scitech USA to import and market Recombinant Human
- Insulin, Hepatitis B Vaccine & Growth Hormone (BTGC acquired by Ferring).
- License agreement with Bioton, Poland, to import Recombinant Human Insulin Crystals and finished formulation of Recombinant Human Insulin Cartridges through SciGen.
- License agreement with Biotech GmBH, Germany (BBT) to market Gonadotropins in India.
- License agreement with Generex Biotechnology Corporation, Canada / USA to distribute and market Oral Recosulin, ‘Oral-Lyn’ on an exclusive basis in Indian sub-continent which includes India, Nepal, Pakistan, Bhutan, Bangladesh, Srilanka & Myanmar .
- Licence agreement with Lallemand and Institute Rosell, France, to market Probiotics.